Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Queen Mary University of London and OCDEM researchers develop alternative treatment for patients as young as three months.

Photo of baby feet

In a new study, published in the journal NEJM, scientists including Professor Rajesh Thakker, have developed a new way to treat patients with low blood calcium values and recurrent seizures caused by a genetic condition known as autosomal dominant hypocalcaemia type 1(ADH1). This condition reduces secretion of parathyroid hormone (PTH) and also increases urine calcium excretion.

The study used subcutaneous PTH infusions delivered by a portable pump (approx 6x3x1 cm), that is usually used for insulin treatment in patients with diabetes mellitus, in patients with ADH1 for whom conventional treatment with tablets of a drug called alpha-calcidol was insufficient.

The PTH infusion stopped seizures in all patients, reduced hospital admissions, and also increased calcium concentrations, without increasing urine calcium excretion. Treatment was given to a total of 6 patients, of which 4 were below 1 years old and 3 were below 3 months old, and has continued for an average of 3.5 years for the duration of the study.

Dr Evelien Gevers, Clinical Reader at The Centre of Endocrinology, Queen Mary University of London and Consultant Paediatric Endocrinologist at Royal London Children’s Hospital (part of Barts Health NHS Trust), said: “Our findings are important as all patients that started below 1 years old had normal developmental milestones. PTH treatment using portable insulin pumps is feasible even over many years and in small babies, and is a more physiological treatment for ADH1 and also for other forms of hypoparathyroidism, at least until other treatment options are available.”

Read the paper

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

EASD-Robert Turner Clinical Research Training Course

This interactive and highly successful course returns to the face-to-face format in 3-7 April 2022 for its 18th year.

RDM researchers awarded Oxford-Bristol Myers Squibb Fellowships

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Six new Oxford-BMS Fellowships for 2021 were announced.

Changes in blood cell production over the human lifetime may hold clues to patterns of disease

A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.